경희대학교병원 간암 다학제증례집담회 Multidisciplinary case conference Liver Cancer Conference 소화기 센터 회의실 2013.6.21.

Slides:



Advertisements
Similar presentations
Intermediate stage HCC management
Advertisements

Staging Strategy and Treatment for Patients With HCC
WY Chu, Surgery, Tuen Mun Hospital, NTWC.  Initial management as a HST in rupture HCC.
Radiotherapeutic Option in Management of Hepatocellular Carcinoma
High-Intensity Focused Ultrasound for Hepatocellular Carcinoma Joint Hospital Surgical Grand Round Queen Mary Hospital 19/10/2013.
Ayman Abdo MD, AmBIM, FRCPC
Hepatocellular Carcinoma Detection and Treatment
HCC Guidelines and recommendation Typical feature (wash in/wash out) New mass/nodule NoYes Alternative imaging technique Atypical featureTypical.
Hepatocellular Carcinoma Diagnostic and Therapeutic Strategies
Epidemiology  Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer.  Worldwide, its prevalence follows that of hepatitis B.
HEPATOCELLULAR CARCINOMA Monton. HCC in Thailand Most common cancer in Thai male Incidence 5 x 100,000 / year Male : female = 3-8:1 Age > 40 yr.
Chronic liver disease Cirrhosis hepatic Encephalopathy Dr. Yasir M Khayyat MBcHB,FRCPC,FACP,ABIM Assistant professor of Medicine Faculty of Medicine Umm.
Guzman, Alexander Joseph Hipolito, April Lorraine
Hepatocellular Carcinoma (HCC). Definition : Hepatocellular carcinoma is a primary malignancy of the hepatocyte, also known as liver cell carcinoma. Types.
Hamid Tavakkoli, MD Associate Prof. of Gastroenterology.
HEPATIC TUMORS Dr.Cengiz Pata Gastroenterology Department Yeditepe University,Istanbul.
HCC Guidelines
SYB Case #2 Jordan Torok Class of 2010 December 11 th, 2008.
Student SYB Chet Cunha MS IV January 22, History 61 y/o M with known HCV x 5 yrs. presenting with vague abdominal discomfort. Outside CT showed.
HCC Guidelines and recommendation Diagnostic algorithm and recall policy.*One imaging technique only recommended in centers of excellence with high-end.
Clinical History Patient presents with a palpable upper abdominal mass Patient states possible clinical history of abdominal hernia.
Chief Complaint back pain Present Illness 73/F, DM, colon Ca. op. s/p CTx. Hx.( 송도병원 ) 있는 자로, infectious arthritis, Rt. shoulder 있어 성심병원 입원하여 I&D.
Chief Complaint Rectal cyst Present Illness F/50, HBV carrier 이외 특이 병력 없는 환자로 건강 검진으로 시행한 CFS 에서 rectal cyst 발견되어 큰 병원 진료 권유받고 본원 소화기 내과 방문 후 내시경적 절제 불가하여.
 Macroscopic anatomy › External view › The quadrate lobe belongs anatomically to the right lobe and functionally to the left
경희대학교병원 간암 다학제증례집담회 Multidisciplinary case conference Liver Cancer Conference 소화기 센터 회의실
Hamid Tavakkoli, MD Associate Prof. of Gastroenterology.
경희대학교병원 간암 다학제증례집담회 Multidisciplinary case conference Liver Cancer Conference 소화기 센터 회의실
Case 장 O 순 F/74 adm C.C) known hepatic mass P.I) F/74. CHB, HTN, CRF d/t GN 으로 본원 IN prof. 정경환 f/u 하고 있으 며 B-viral LC c ascites.
History Case 양 O 환 M/62 DM (+), HTN (+) Alcohol Hx (+) 소주 1 병 x 2 회 / 주 Smoking Hx (+) 0.5 x 30 p-y  62/M DM, HTN, Chronic hepatitis B 로 local.
경희대학교병원 간암 다학제증례집담회 Multidisciplinary case conference Liver Cancer Conference 소화기 센터 회의실
Case 권 O 범 M/44 adm C.C) for evaluation of recurrent HCC & TACE #2 P.I) DM, HTN 있고, SAH d/t aneurysmal rupture (Rt. ACOM)
Management of Hepatocellular carcinoma
경희대학교병원 간암 다학제증례집담회 Multidisciplinary case conference Liver Cancer Conference 소화기 센터 회의실
경희대학교병원 간암 다학제증례집담회 Multidisciplinary case conference Liver Cancer Conference 소화기 센터 회의실
GASTROENTEROLOGY 2010;138:493–502 심 재 준 월요 저널.
조기위암 내시경 절제, 그 후 소화기내과 R1 박민아 /prof. 장재영. 주소 뒤무직 onset : 3 개월 전 현병력 3 개월 전부터 뒤무직, 소화불량 있어 1 개월 전에 본원에서 상부위장관내 시경을 시행받았음. 조기위암 의심되어 진단 및 치료 위해 입원함. 증례.
경희대학교병원 간암 다학제증례집담회 Multidisciplinary case conference Liver Cancer Conference 소화기 센터 회의실
Liver Transplantation Conference 경희대학교 병원 간이식팀 R3 최인승 /Prof. 김병호
Case 박성진 M/66 adm C.C) for TACE #2 P.I) 66/M CHB 로 2006 년부터 본원 IG f/u 중인자로 HCC 진단 받고 TACE #1, RFA #1 시행한 자로
경희대학교병원 간암 다학제증례집담회 Multidisciplinary case conference Liver Cancer Conference 소화기 센터 회의실
경희대학교병원 간암 다학제증례집담회 Multidisciplinary case conference Liver Cancer Conference 소화기 센터 회의실
경희대학교병원 간암 다학제증례집담회 Multidisciplinary case conference Liver Cancer Conference 소화기 센터 회의실
Differential Diagnosis
Benign Liver Masses in HIV Patient
Experience of ALPPS procedure in treating hepatocellular carcinoma
Dr. Mohammed Omar Khalifa
Hepatocellular Carcinoma: Diagnosis and Management
Living donor liver transplantation Pre-transplant report
Missing Cirrhosis on CT Scan
The Value of Measurement of Circulating Tumor Cells in Hepatocellular Carcinoma Nashwa Sheble, Gehan Hamdy, Moones A Obada, Gamal Y Abouria, Fatma Khalaf.
Chemotherapy for Liver Metastasis Originating from Colorectal Cancer with Portal Vein Tumor Thrombosis: A Case Report Case Rep Oncol 2013;6:
History 24 Year old woman 6 Months of age “severe cholangitis’’ emergently decompressed via cholecystostomy tube choledochal cyst noted Definitive surgery:
Liver Cancer Conference
Liver Transplantation Conference
Case Presentation R2 이은정.
HCC.
Successful TACE for HCC
Recurrent Hepatitis C Post OLT for HCC and Cirrhosis
Chapter 14 Hepatic Tumors, Malignant 1
Cholangiocarcinoma in HBV Non-Cirrhotic
Successful TACE followed by OLT for HCC in Alcoholic Cirrhosis
Successful Tace in Patient with large HCC
History 56 y/o male from Cuba newly diagnosed with hepatitis C genotype 2b in Jan 2008 No symptoms of decompensation.
HEPATOCELLULAR CARCINOMA (HCC) at
Case 윤O현 M/63 adm C.C) for TACE
Epidemiology & First option of treatment
Does Liver Regeneration Increase the Postoperative HCC Recurrence after Curative Resection ? Jin-Ho Lee, MD. Department of Surgery, Yonsei University.
KAHBPS , Gyeongju, Korea Long-term outcome after resection of huge hepatocellular carcinoma ≥10 cm: Single-institution experience with 471 patients:
Bile duct invasion itself can be the prognosis factor in early HCC
Multidisciplinary team approach to hepatocellular carcinoma management in a liver transplant center from Romania Cerban R.1, Iacob S.1, Croitoru A.1, Popescu.
Presentation transcript:

경희대학교병원 간암 다학제증례집담회 Multidisciplinary case conference Liver Cancer Conference 소화기 센터 회의실

 B-viral LC 와 DM 으로 한양대 병원 f/u 해옴  ‘ Angina 로 심장내과 입원해 시행한 Abd US 상 suggestive of HCC at S5/7, Liver MR 상 HCC at S7 → TACE #1 (’ )  ‘ CT : no recurrence of HCC  ’ CT : no recurrence of HCC  ’ MR : Viable tumor at the posterior aspect to the lipiodolized HCC at S7  토의 목적 : 향후 치료 방향 논의 (op or intraop RF?) History Case 김 O 열 M/49 DM/HTN/TBc/Hepatitis(+/-/-/+) : HBV carrier – Baraclude 0.5mg qd 복용 중 B-viral LC (Child A(5), MELD 5.68) with esophageal varix Op Hx (-) Alcohol Hx (-), Smoking Hx (+) : 20py

Underlying liver function and performance status CBC/DC WBC(mm 3 )4,100 Hb(g/dl)14.7 PLT(mm 3 )107,000 PT(sec)14.7 INR1.17 Performance status: Grade 0 Chemistry TB/DB(mg/dL)1.07/- AST/ALT(IU/L)27/25 ALP/rGT(IU/L)54/- Prot/Alb(g/dL)8.0/4.4 BUN/Cr(mg/dL)-/- LC & Stage Child-PughA (5) MELD score5.68 Esophageal varices+ Ascites- Encephalopathy 김 O 열 M/49 Case 1 Tumor markers AFP (ng/mL)60.54 CEA (ng/mL) - PIVKA II (mAU/mL)15 CA Viral markers/ underlying liver disease HBV / HCV(+/-) HBeAg / HBeAb(-/+) Virus titer<20 IU/mL Antiviral TxBaraclude 0.5mg Alcohol-

’ ‘ ’13.3. ‘13.6. TACE #1 (’ ) TACE #1 (’ ) Angina s/p PCI HCC at S7 Angina s/p PCI HCC at S 조 O 복 F/57 B-viral LC DM B-viral LC DM CT : no recurrence Case 1 Tumor Stage and Clinical Course 김 O 열 M/49 MR : viable tumor at S7 12 년 10 월 12 년 12 월 13 년 3 월 13 년 6 월 AFP PIVKA Ⅱ PET-CT ( ) 1. C/W HCC at segment VII of liver 2. No abnormal hypermetabolic lesion suggesting metastasis *Liver-MRI ( ) Viable tumor at the posterior aspect to the lipiodolized HCC at S7. CT : no recurrence

ART score system

ART score 김 O 열 M/49 Case 1 indexfindingsscoreNET score Child-Pugh score increase Absent point1.5 + ≥2 points3 AST increase (≥ 25%) Absent0 Present4 Radiologic tumor response Present (CR, PR)0 Absent (SD, PD)1

Summary – 치료 방침 결정 김 O 열 M/49 Case 1 Current liver function Normal Well preserved (no risk of decompensation) Compensated (risk of decompensation) Decompensated Terminal state Extent of current tumor Localized (curative) Locally advanced (resectable) Locally advanced (unresectable) No < 4 Diffuse or multiple (> 3) Initial Tumor stage Date: 2012 년 10 월 Modified UICC ( 대한간암연구학회 ) T 2 N 0 M 0 Stage II JIS score 1 BCLC stage Very early / Early / Intermediate / Advanced / Terminal Current status Locally advanced with well preserved liver function Risk factors of recurrence / Tumor biology Extrahepatic metastasis N Tumor size > 5 cm, capsulation N Tumor number 1 Repeated TACE ( 1 회 / 기간 ) 0 Vascular or bile duct invasion N High uptake of PET Y High AFP or PIVKA II Y Not normalized AFP after curative Tx Y Histology (microvascular invasion) - Histology (satellite lesion, differentiation) - Poor control of underlying liver disease N ART score 1

 ’11.5. Chronic hepatitis C : ‘11.7~11. interferon 투약 중 부작용으로 중단  ‘12.2. CT : HCC at S8 → TACE #1 (‘ )  ‘13.2. MR : Recurrence of lipiodolized HCC at S4/8 → TACE #2 (‘ )  ‘13.5. MR : Suggested viable HCC at S4/8  토의 목적 : 영상 소견에 대한 논의 History Case 이 O 복 M/62 DM/HTN/TBc/Hepatitis(-/-/-/+) : CHC C-viral LC (Child A(5), MELD 5.61) Op Hx (-) Alcohol Hx (-), Smoking Hx (+) : 30py

Underlying liver function and performance status CBC/DC WBC(mm 3 )5,910 Hb(g/dl)13.0 PLT(mm 3 )350,000 PT(sec)14.7 INR1.17 Performance status: Grade 0 Chemistry TB/DB(mg/dL)0.54/- AST/ALT(IU/L)23/15 ALP/rGT(IU/L)179/- Prot/Alb(g/dL)8.5/4.6 BUN/Cr(mg/dL)-/- LC & Stage Child-PughA (5) MELD score5.61 Esophageal varices- Ascites- Encephalopathy 이 O 복 M/62 Case 2 Tumor markers AFP (ng/mL)5.34 CEA (ng/mL) 2.18 PIVKA II (mAU/mL)30 CA Viral markers/ underlying liver disease HBV / HCV(-/+) HBeAg / HBeAb(-/-) Virus titer0 IU/mL Antiviral Tx- Alcohol-

’11.5. ‘12.2. ‘13.2. ‘13.5. CT : HCC at S 조 O 복 F/57 CHC CHC Case 2 Tumor Stage and Clinical Course 이 O 복 M/62 TACE #2 (‘ ) Liver MRI ( ) Suggested viable HCC between the right hepatic lobe and the right diaphragm. Additional lipiodol uptake within the previously noted viable portion of HCC at S4/8 with disappearance of hepatic cysts. Multiple AP shunts and hepatic cysts at both lobes. Hepatic necrosis at S8 and ischemia at S7. Liver cirrhosis. PET-CT ( ) Post-TACE state, unremarkable No abnormal hypermetabolic lesion suggesting distant metastasis MR : Recur of HCC at S4/8 TACE #1 (‘ ) MR : Suggested viable HCC at S4/8 12 년 1 월 12 년 3 월 12 년 7 월 12 년 10 월 13 년 1 월 13 년 5 월 AFP PIVKA II

ART score 이 O 복 M/62 Case 2 indexfindingsscoreNET score Child-Pugh score increase Absent point1.5 + ≥2 points3 AST increase (≥ 25%) Absent0 Present4 Radiologic tumor response Present (CR, PR)0 Absent (SD, PD)1

Summary – 치료 방침 결정 이 O 복 M/62 Case 2 Current liver function Normal Well preserved (no risk of decompensation) Compensated (risk of decompensation) Decompensated Terminal state Extent of current tumor Localized (curative) Locally advanced (resectable) Locally advanced (unresectable) No < 4 Diffuse or multiple (> 3) Initial Tumor stage Date: 2012 년 2 월 Modified UICC ( 대한간암연구학회 ) T 2 N 0 M 0 Stage II JIS score 1 BCLC Very early / Early / Intermediate / Advanced / Terminal Current status Localized advanced with well preserved liver function Risk factors of recurrence / Tumor biology Extrahepatic metastasis N Tumor size > 5 cm, capsulation N Tumor number 2 Repeated TACE ( 1 회 / 기간 ) 1 Vascular or bile duct invasion - High uptake of PET - High AFP or PIVKA II Y Not normalized AFP after curative Tx - Histology (microvascular invasion) - Histology (satellite lesion, differentiation) - Poor control of underlying liver disease N ART score 0

History Case 조 O 웅 M/68 DM/HTN/Tb/Hepatitis(+/+/-/-) Cryptogenic LC c esophageal varix Op Hx (-) Family Hx (-) Alcohol Hx (+) : social drinking, Smoking Hx (-)  ’ Cryptogenic LC with esophageal varix 로 본원 소화기내과 외래 내원  ‘ CT : HCC(2.4cm) at S6 → TACE #1 (’13.6.5)  ‘ CT : TCC → MR : small TCC at LK upper pole → URO f/u  토의 목적 : 향후 치료 방향 논의

Underlying liver function and performance status CBC/DC WBC(mm 3 )4,450 Hb(g/dl)12.9 PLT(mm 3 )129,000 PT(sec)13.7 INR1.08 Performance status: Grade 0 Chemistry TB/DB(mg/dL)0.60/0.19 AST/ALT(IU/L)54/27 ALP/rGT(IU/L)176/328 Prot/Alb(g/dL)8.0/4.2 BUN/Cr(mg/dL)16/0.9 LC & Stage Child-PughA (5) MELD score4.25 Esophageal varices Fundic varices +-+- Ascites- Encephalopathy 조 O 웅 M/68 Case 3 Tumor markers AFP (ng/mL)27.35 CEA (ng/mL) 4.16 PIVKA II (mAU/mL)16 CA19-9 (U/mL) 2.00 Viral markers/ underlying liver disease HBV / HCV(-/-) HBeAg / HBeAb(-/-) Virus titer0 IU/mL Antiviral Txnone Alcohol(+) : social drinking

Tumor Stage and Clinical Course ’ ‘13.5. Case 조 O 웅 M/68 *Kidney & adrenal MR ( ) Possible small TCC at upper pole calyx and renal pelvis of left kidney. - no evidence of renal parenchymal invasion. Early HCC at liver S6. A left renal cyst. PET ( ) No visible hypermetabolic activity of known HCC on S6 C/W malignant mass at upper pole calyx of left kidney Cryptogenic LC c EV Cryptogenic LC c EV HCC at S6 HCC at S6 TACE #1 (‘13.6.5) 13 년 2 월 AFP PIVKA Ⅱ 16

Summary – 치료 방침 결정 조 O 웅 M/68 Case 3 Current liver function Normal Well preserved (no risk of decompensation) Compensated (risk of decompensation) Decompensated Terminal state Extent of current tumor Localized (curative) Locally advanced (resectable) Locally advanced (unresectable) No < 4 Diffuse or multiple (> 3) Initial Tumor stage Date: 2013 년 5 월 Modified UICC ( 대한간암연구학회 ) T 2 N 0 M 0 Stage II JIS score 1 BCLC Very early / Early / Intermediate / Advanced / Terminal Current status Localized with well preserved liver function Risk factors of recurrence / Tumor biology Extrahepatic metastasis N Tumor size > 5 cm, capsulation N Tumor number 1 Repeated TACE ( 1 회 / 기간 ) - Vascular or bile duct invasion N High uptake of PET Y High AFP or PIVKA II Y Not normalized AFP after curative Tx - Histology (microvascular invasion) - Histology (satellite lesion, differentiation) - Poor control of underlying liver disease N ART score -

 HTN, DM, B-viral LC 로 local clinc f/u 중 HCC 의심 소견 (mass at S5, AFP 상승 ) 으 로 소화기내과 외래 내원  ’13.1. CT : HCC at right AI segment, Malignant portal vein thrombosis  ‘13.1. MR : Huge HCC in Rt hepatic lobe with multi-nodular HCCs → TACE #1 at Rt AI segment & TAE #1 at lateral segment (‘ ) → Tomotherapy to Rt lobe (‘13.2.4~’13.3.5)  ‘13.4. CT : Increased size and extent of multifocal arterial enhancing lesions in Rt lobe of liver, HCCs and Malignant thrombus with AP shunt in right portal vein  ‘13.6. MR f/u 예정  토의 목적 : Tomotherapy 후 치료 반응 평가 및 향후 치료 방침 논의 History Case 안 O 석 M/61 DM/HTN/TBc/Hepatitis(+/+/-/+) : CHB B-viral LC(Child A(5), MELD 3.60), GU Op Hx (+) : HIVD op Alcohol Hx (+) : 소주 1~1.5 병 / 회, 3 회 / 주, Smoking Hx (+) : 2p x 20y

Underlying liver function and performance status CBC/DC WBC(mm 3 )3,190 Hb(g/dl)15.1 PLT(mm 3 )71,000 PT(sec)12.6 INR0.95 Performance status: Grade 0 Chemistry TB/DB(mg/dL)0.59/- AST/ALT(IU/L)36/49 ALP/rGT(IU/L)88/62 Prot/Alb(g/dL)6.6/3.9 BUN/Cr(mg/dL)-/- LC & Stage Child-PughA(5) MELD score3.60 Esophageal varices- Ascites- Encephalopathy 안 O 석 M/61 Case 4 Tumor markers AFP (ng/mL)3,068 CEA (ng/mL) 1.75 PIVKA II (mAU/mL)92 CA Viral markers/ underlying liver disease HBV / HCV(+/-) HBeAg / HBeAb(-/+) Virus titer<20 Antiviral Tx- Alcohol-

‘13.1. ‘13.4. ‘13.6. CT : HCC with malig PVT MR : Huge HCC with multi-nodular HCCS CT : HCC with malig PVT MR : Huge HCC with multi-nodular HCCS 조 O 복 F/57 B-viral LC Case 4 Tumor Stage and Clinical Course 안 O 석 M/61 Liver-TACE CT ( ) Three lipiodolized recurrent HCC in S5/8, S7 and dome area of right AS, and left lateral segment Increased size and extent of multifocal arterial enhancing lesions in right lobe of liver, HCCs. Malignant thrombus with Ap shunt in right portal vein. A lipiodolized mass without viable tumor in S3. Rec;liver MR PET-CT ( ) Known HCC in the right lobe with right portal vein thrombosis No abnormal hypermetabolic lesion suggesting distant metastasis CT : increasing size & extent of HCC Malignant PVT CT : increasing size & extent of HCC Malignant PVT MR f/u TACE & TAE #1(‘ ) Tomotherapy (‘13.2.4~’13.3.5) 13 년 1 월 13 년 2 월 13 년 4 월 13 년 5 월 13 년 6 월 AFP PIVKA II

ART score 안 O 석 M/61 Case 4 indexfindingsscoreNET score Child-Pugh score increase Absent point1.5 + ≥2 points3 AST increase (≥ 25%) Absent0 Present4 Radiologic tumor response Present (CR, PR)0 Absent (SD, PD)1

Summary – 치료 방침 결정 안 O 석 M/61 Case 4 Current liver function Normal Well preserved (no risk of decompensation) Compensated (risk of decompensation) Decompensated Terminal state Extent of current tumor Localized (curative) Locally advanced (resectable) Locally advanced (unresectable) No < 4 Diffuse or multiple (> 3) Initial Tumor stage Date : 2013 년 1 월 Modified UICC ( 대한간암연구학회 ) T 3 N 0 M 0 Stage III JIS score 2 BCLC Very early / Early / Intermediate / Advanced / Termin Current status Diffuse or multiple with well preserved liver function Risk factors of recurrence / Tumor biology Extrahepatic metastasis N Tumor size > 5 cm, capsulation Y Tumor number multiple Repeated TACE ( 1 회 / 기간 ) N Vascular or bile duct invasion N High uptake of PET Y High AFP or PIVKA II Y Not normalized AFP after curative Tx Y Histology (microvascular invasion) - Histology (satellite lesion, differentiation) - Poor control of underlying liver disease N ART score 1